NASDAQ: OCUPOcuphire Pharma Inc Stock
$1.67-0.07 (-4.02%)
Updated Apr 18, 2024
OCUP Price
$1.67
Fair Value Price
N/A
Market Cap
$41.44M
52 Week Low
$1.67
52 Week High
$6.60
P/E
-3.63x
P/B
0.83x
P/S
3.41x
PEG
N/A
Dividend Yield
N/A
Revenue
$19.05M
Earnings
-$9.99M
Gross Margin
100%
Operating Margin
-52.36%
Profit Margin
-52.4%
Debt to Equity
0.08
Operating Cash Flow
-$1M
Beta
0.71
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
OCUP Overview
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how OCUP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OCUP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OCUP is good value based on its book value relative to its share price (0.83x), compared to the US Biotechnology industry average (5.76x)
P/B vs Industry Valuation
OCUP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OCUP due diligence checks available for Premium users.
Be the first to know about important OCUP news, forecast changes, insider trades & much more!
OCUP News
Valuation
OCUP fair value
Fair Value of OCUP stock based on Discounted Cash Flow (DCF)
Price
$1.67
Fair Value
$4.56
Undervalued by
63.39%
OCUP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
OCUP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.63x
Industry
15.68x
Market
41.33x
OCUP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.83x
Industry
5.76x
OCUP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OCUP's financial health
Profit margin
Revenue
$1.7M
Net Income
-$4.8M
Profit Margin
-283.6%
OCUP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OCUP's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$53.9M
Liabilities
$4.0M
Debt to equity
0.08
OCUP's short-term assets ($53.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OCUP's short-term assets ($53.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OCUP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OCUP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$4.5M
Investing
$0.0
Financing
$3.6M
OCUP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OCUP vs Biotech Stocks
Ocuphire Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.